Cue Biopharma Inc. – Material Contracts Watch

from 10-Q 9 pages Separation and Release of Claims Agreement

from 10-Q 17 pages Amended and Restated Executive Employment Agreement This Amended and Restated Executive Employment Agreement (The “Agreement”) Is Made by and Between Cue Biopharma, Inc., a Delaware Corporation (“CUE” or the “Company”), and Lucinda Warren (“Executive,” and Together With CUE, the “Parties”). Whereas, the Company and Executive Desire to Enter Into This Agreement to Set Forth the Conditions Under Which the Executive Will Continue to Be Employed by the Company. Now, Therefore, in Consideration of the Foregoing, of the Mutual Promises Contained Herein and of Other Good and Valuable Consideration, the Receipt and Sufficiency of Which Are Hereby Acknowledged, the Parties Hereby Agree as Follows as of the Effective Date (As Defined Below): 1. Position and Duties

from 10-Q 7 pages Third Amendment to Rider to License Agreement Vivarium

from 8-K 18 pages Cue Biopharma, Inc. 2026 Inducement Stock Incentive Plan

from 8-K 26 pages Registration Rights Agreement

from 8-K 38 pages Securities Purchase Agreement

from 8-K 18 pages Investor Agreement by and Between Ascendant Health Sciences Ltd. and Cue Biopharma, Inc. Dated as of [ ], 2026 Investor Agreement

from 8-K 36 pages Securities Purchase Agreement by and Between Ascendant Health Sciences Ltd. and Cue Biopharma, Inc. Dated as of April 30, 2026 Securities Purchase Agreement

from 10-K 57 pages Option Agreement

from 10-K 8 pages Separation and Release of Claims Agreement

from 10-K 19 pages This Executive Employment Agreement (The “Agreement”) Is Made by and Between Cue Biopharma, Inc., a Delaware Corporation (“CUE” or the “Company”), and Lucinda Warren (“Executive,” and Together With CUE, the “Parties”)

from 10-K 3 pages Cue Biopharma, Inc. Director Compensation Policy

from 10-K 5 pages For Good and Valuable Consideration, Cue Biopharma, Inc. (The “Company”) Hereby Grants, Pursuant to the Provisions of the Cue Biopharma, Inc. 2025 Stock Incentive Plan (The “Plan”), to the Participant Designated Below, an Non-Qualified Stock Option to Purchase the Number of Shares Specified Below (The “Option”). the Option Shall Be Subject to This Notice of Grant (The “Notice of Grant”) and the Attached Terms and Conditions of Stock Option (Together With the Notice of Grant, the “Award Agreement”). Participant: Type of Option: Non-Qualified Stock Option Grant Date: Number of Shares Purchasable: Option Exercise Price Per Share: Final Exercise Date: Vesting Schedule: In No Event May the Option Be Exercised After the Final Exercise Date as Provided Above. the Company, by Its Duly Authorized Officer, and the Participant, Hereby Execute This Award Agreement. Participant Cue Biopharma, Inc. Sign Name: Sign Name: Print Name: Print Name: Title: Stock Option Agreement Incorporated Terms and Conditions 1. Grant of Option

from 10-K 6 pages Participant: Type of Option: Incentive Stock Option Grant Date: Number of Shares Purchasable: Option Exercise Price Per Share: Final Exercise Date: Vesting Schedule: The Option Will Become Exercisable Over Four Years, With One-Fourth Vesting on the One-Year Anniversary of the Grant Date, and the Balance Vesting Quarterly Thereafter Until the Fourth Anniversary of the Grant Date. All Vesting Is Dependent on the Participant Remaining an Eligible Participant, as Provided Herein. in No Event May the Option Be Exercised After the Final Exercise Date as Provided Above. the Company, by Its Duly Authorized Officer, and the Participant, Hereby Execute This Award Agreement. Participant Cue Biopharma, Inc. Sign Name: Sign Name: Print Name: Print Name: Title: Stock Option Agreement Incorporated Terms and Conditions 1. Grant of Option

from 10-Q 5 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Attachment a Advisor Agreement

from 10-Q 9 pages Separation and Release of Claims Agreement

from 10-Q 17 pages (“Executive,” and Together With CUE, the “Parties”)

from 10-Q 3 pages Second Amendment to License Agreement

from 10-Q 11 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Boehringer Ingelheim Amendment to the Amended and Restated License Agreement

from 10-Q 70 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Collaboration and License Agreement by and Between Boehringer Ingelheim International Gmbh and Cue Biopharma, Inc. Bi Contract No.: 926652 Bi Po No.: 43116788 1 Collaboration and License Agreement